Natixis’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $23.5M | Sell |
293,673
-21,850
| -7% | -$1.8M | 0.08% | 164 |
|
|
2025
Q4 | $26.9M | Sell |
315,523
-10,891
| -3% | -$894K | 0.1% | 164 |
|
|
2025
Q3 | $25.4M | Buy |
326,414
+12,031
| +4% | +$940K | 0.12% | 156 |
|
|
2025
Q2 | $24.6M | Buy |
314,383
+84,139
| +37% | +$6.28M | 0.11% | 128 |
|
|
2025
Q1 | $16.6M | Sell |
230,244
-15,967
| -6% | -$1.14M | 0.09% | 165 |
|
|
2024
Q4 | $18.2M | Buy |
246,211
+112,637
| +84% | +$7.88M | 0.11% | 142 |
|
|
2024
Q3 | $8.81M | Sell |
133,574
-262,631
| -66% | -$19.1M | 0.05% | 242 |
|
|
2024
Q2 | $36.6M | Buy |
396,205
+293,904
| +287% | +$26M | 0.21% | 82 |
|
|
2024
Q1 | $9.78M | Sell |
102,301
-96,945
| -49% | -$8.14M | 0.05% | 237 |
|
|
2023
Q4 | $15.2M | Sell |
199,246
-358,814
| -64% | -$25M | 0.11% | 164 |
|
|
2023
Q3 | $38.7M | Buy |
558,060
+275,029
| +97% | +$22.1M | 0.3% | 73 |
|
|
2023
Q2 | $26.7M | Buy |
283,031
+222,318
| +366% | +$19.3M | 0.22% | 102 |
|
|
2023
Q1 | $5.02M | Sell |
60,713
-102,984
| -63% | -$8.09M | 0.05% | 272 |
|
|
2022
Q4 | $12.2M | Buy |
163,697
+7,121
| +5% | +$549K | 0.07% | 237 |
|
|
2022
Q3 | $13.1M | Buy |
156,576
+106,122
| +210% | +$10.2M | 0.06% | 233 |
|
|
2022
Q2 | $4.8M | Sell |
50,454
-42,180
| -46% | -$4.37M | 0.02% | 457 |
|
|
2022
Q1 | $10.9M | Buy |
92,634
+72,397
| +358% | +$8.12M | 0.04% | 402 |
|
|
2021
Q4 | $2.62M | Sell |
20,237
-9,681
| -32% | -$1.13M | 0.01% | 704 |
|
|
2021
Q3 | $3.39M | Sell |
29,918
-10,277
| -26% | -$1.17M | 0.01% | 627 |
|
|
2021
Q2 | $4.16M | Sell |
40,195
-75,721
| -65% | -$7.14M | 0.02% | 415 |
|
|
2021
Q1 | $9.7M | Sell |
115,916
-8,171
| -7% | -$691K | 0.03% | 383 |
|
|
2020
Q4 | $11.3M | Buy |
+124,087
| New | +$10.3M | 0.04% | 363 |
|
|
2020
Q3 | – | Sell |
-22,377
| Closed | -$1.55M | – | 799 |
|
|
2020
Q2 | $1.55M | Sell |
22,377
-100,716
| -82% | -$7.16M | 0.01% | 459 |
|
|
2020
Q1 | $7.74M | Buy |
123,093
+71,547
| +139% | +$5.16M | 0.06% | 222 |
|
|
2019
Q4 | $3.99M | Sell |
51,546
-179,148
| -78% | -$14M | 0.02% | 446 |
|
|
2019
Q3 | $16.9M | Buy |
+230,694
| New | +$16.2M | 0.11% | 181 |
|
|
2018
Q3 | – | Sell |
-102,705
| Closed | -$4.98M | – | 864 |
|
|
2018
Q2 | $4.98M | Sell |
102,705
-9,633
| -9% | -$450K | 0.03% | 382 |
|
|
2018
Q1 | $5.22M | Buy |
112,338
+65,199
| +138% | +$2.83M | 0.03% | 356 |
|
|
2017
Q4 | $1.77M | Sell |
47,139
-52,173
| -53% | -$1.91M | 0.01% | 429 |
|
|
2017
Q3 | $3.62M | Buy |
+99,312
| New | +$3.79M | 0.03% | 322 |
|
|
2017
Q2 | – | Sell |
-13,125
| Closed | -$412K | – | 868 |
|
|
2017
Q1 | $412K | Buy |
+13,125
| New | +$411K | 0.01% | 568 |
|
|
2015
Q2 | – | Sell |
-29,586
| Closed | -$702K | – | 395 |
|
|
2015
Q1 | $702K | Buy |
+29,586
| New | +$664K | 0.01% | 272 |
|
Other funds holding EW
VCM
VPM
Natixis's EW Position: Q1 2026 in Review
Natixis reduced its Edwards Lifesciences (EW) stake by 6.9% in Q1 2026, selling an estimated $1.8M and leaving 293,673 shares worth $23.5M. The position accounts for 0.08% of the portfolio, ranked #164.
Natixis first reported a position in EW in Q1 2015 and has held it in 32 quarters since. The position peaked at $38.7M in Q3 2023. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.
- Natixis held 293,673 shares of Edwards Lifesciences worth $23.5M as of Q1 2026.
- Natixis sold 21,850 Edwards Lifesciences shares in Q1 2026, an estimated $1.8M.
- Edwards Lifesciences made up 0.08% of Natixis's portfolio in Q1 2026, its #164 holding.
- Natixis first reported a position in Edwards Lifesciences in Q1 2015 and has held it in 32 quarters since.
- Natixis's Edwards Lifesciences position peaked at $38.7M in Q3 2023.
- 1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.
Based on Natixis's 13F filing for Q1 2026, filed 14 May 2026.